48周减重15.1%，药效堪比礼来！中国原研的“减肥神药”来了

Core Insights - The obesity treatment drug Ecnoglutide developed by Hangzhou Xianweida Biotechnology Co., Ltd. has shown strong performance in Phase III clinical trials, with patients losing an average of over 15% of their weight after 48 weeks of treatment, marking a significant step for China in the global weight loss drug market [1][3]. Group 1: Clinical Trial Results - The SLIMMER study, the largest Phase III clinical trial for weight loss drugs in China, involved 664 patients with obesity or overweight conditions, demonstrating a weight reduction of 15.4% in the 2.4mg dosage group after 48 weeks [3]. - 93% of patients receiving the highest dose of Ecnoglutide experienced at least a 5% weight loss, outperforming similar drugs in China [1][3]. Group 2: Drug Mechanism and Advantages - Ecnoglutide is the first biased GLP-1 receptor agonist to complete Phase III clinical trials globally, working similarly to Novo Nordisk's Semaglutide by mimicking the natural hormone GLP-1 to regulate blood sugar and appetite [4]. - The structural differences of Ecnoglutide may provide it with greater efficacy and safety compared to other GLP-1 receptor agonists [4]. Group 3: Market Competition and Outlook - Upon approval, Ecnoglutide will compete with Novo Nordisk's Semaglutide, Eli Lilly's Tirzepatide, and other weight loss drugs in the Chinese market, which is projected to exceed 100 billion RMB [5]. - There are over 30 experimental weight loss drugs in the late-stage pipeline in China, indicating increasing competition in the market [5].